Nachrichten zur Eli Lilly & Co. Aktie

Eli Lilly raises annual profit forecast as GLP-1 drugs fuel growth

Eli Lilly raised its annual profit forecast and posted better-than-expected first quarter on Thursday, on steady demand for its ?weight-loss…

Eli Lilly raises annual profit forecast on sustained weight-loss drug demand

Eli Lilly raises annual profit forecast on sustained weight-loss drug demand…

Hims & Hers: The Telehealth Stock Caught Between a Lilly Lifeline and an Amazon Ambush

Hims & Hers navigates a pivotal moment: a new Eli Lilly distribution deal lifts analyst targets, whi…

Mehrere Milliarden-Deals und Medizin-Revolution! Eli Lilly zündet mit Foundayo die nächste Wachstumsstufe!

Der US-Pharmagigant Eli Lilly (LLY) schlägt erneut kräftig auf dem Übernahmemarkt zu und untermauert gleichzeitig mit herausragenden Studiendaten seine Vormachtstellung.…

FDA Update Puts Hims And Hers Weight Loss Partnerships In Focus

Regulators are scheduled to meet in July to discuss FDA guidance that could influence how NYSE:HIMS expands its weight-loss and…

Pharma bets a little-known form of cholesterol will underpin its next blockbuster heart drugs

Novartis, Amgen and Eli Lilly are betting that slashing levels of a particularly bad form of cholesterol could deliver the…

Biggest winner of the amended Microsoft-OpenAI deal — plus, mixed news for Eli Lilly

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly to buy Ajax Therapeutics for up to $2.3 billion in blood cancer bet

Eli Lilly said on Monday it would buy privately held blood cancer treatment developer Ajax Therapeutics for up to $2.3…

Should You Add a Healthcare Stock to Your Portfolio This Month? And Should It Be Eli Lilly (LLY)?

Eli Lilly is a giant in the weight-loss drug realm, and its aiming to grow more.…

A Look At Hims & Hers Health (HIMS) Valuation After Fresh GLP-1 Analyst Endorsement And Pharma Partnerships

Hims & Hers Health (HIMS) is back in focus after fresh analyst coverage spotlighted its Novo Nordisk partnership and broader…

Why Eli Lilly (LLY) Shares Are Trading Lower Today

Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 3.6% in the afternoon session after disappointing weekly prescription numbers for…

Eli Lilly: A Heavyweight Battle Isnt Won In Round 1

…

Stocks making the biggest moves midday: Intel, AMD, Charter, Hims & Hers, Eli Lilly and more

These are the stocks posting the largest moves in midday trading.…

Stocks making the biggest moves midday: Intel, AMD, Charter, Hims & Hers, Eli Lilly and more

These are the stocks posting the largest moves in midday trading.…

How Expanding GLP?1 Offerings and Partnering With LillyDirect At Hims & Hers Health (HIMS) Has Changed Its Investment Story

In recent days, Hims & Hers Health expanded its platform so clinicians can prescribe Eli Lilly GLP?1 weight loss treatments,…

Eli Lillys new GLP-1 pill vs. Wegovy, JPMorgan initiates coverage on Hims

Market Catalysts Host Julie Hyman and Yahoo Finance Senior Reporter Brooke DiPalma track several of the days top trending stock…

Lillys obesity pill hits nearly 4000 prescriptions in second week after launch

Eli Lillys newly launched oral weight loss drug was prescribed 3,707 times in the U.S. in the second week after…

Eli Lilly stock slips despite steady GLP-1 script growth

Eli Lilly stock slips despite steady GLP-1 script growth…

Hims & Hers reverses amid doubts on its newest obesity plan

Hims stock reversed lower Thursday despite new efforts in weight loss that connect patients with Eli Lillys self-pay pricing.…

Eli Lilly (LLY) Expands Partnership with Hims & Hers

The stock of Hims Hers Health ($HIMS) was up as much as 7% after the company announced that it…

Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership

On April 23, 2026, Hims & Hers announced that it has begun providing access to Eli Lillys GLP-1 weight-loss products…

Hims & Hers likely to be up on LillyDirect announcement, says Leerink

Hims Hers (HIMS) announced access to Eli Lilly (LLY) GLP-1 products through its platform, expanding its weight-loss offering, though…

Hims & Hers Health (HIMS) Is Up 19.4% After Expanding GLP-1 Access Via LillyDirect Integration

Earlier this week, Hims & Hers Health said clinicians on its platform can now prescribe Eli Lilly GLP-1 weight loss…

Hims & Hers (HIMS) Stock Jumps 7% After Expanding Eli Lilly GLP-1 Deal

Hims & Hers (HIMS) stock rose 7% after expanding its Eli Lilly deal, adding Zepbound prescriptions to its GLP-1 platform…

Hims Yields Ground in GLP-1 Market. Why Its CEO Is Calling It the Netflix of Pharma.

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims Stock Drops on LillyDirect Deal. Can It Be the Netflix of Pharma?

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims Stock Falls as It Pivots From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing.

Hims & Hers Health will allow providers to prescribe scripts filled by LillyDirect, Eli Lilly’s direct-to-consumer platform.…

Hims & Hers jumps 7% after expanding partnership with Eli Lilly

Hims & Hers Health (NYSE:HIMS) shares climbed 7% after the company revealed an expansion of its platform that allows healthcare…

Hims rises after it says it now offers “full range” of FDA-approved GLP-1s

Hims providers can now send prescriptions to Eli Lilly’s direct-to-consumer pharmacy....…

Why One Analyst Is Dubious On Hims Newest Obesity Plan

Hims stock reversed lower Thursday despite new efforts in weight loss that connect patients with Eli Lillys self-pay pricing.…

Hims & Hers adds Lilly GLP-1 treatments to lineup – CEO compares it to Netflix’s early days

?Hims & Hers CEO Andrew Dudum noted that, like Netflix gave users the choice of what they wanted most, Hims…

Why Hims & Hers stock surged 7% in a single trading day

Hims & Hers Health stock jumped 7% after expanding its platform to include Eli Lillys GLP-1 weight loss medications. Heres…

Hims & Hers stock surges 7% on Eli Lilly partnership expansion

Hims & Hers stock surges 7% on Eli Lilly partnership expansion…

Eli Lilly’s Kelonia Therapeutics acquisition seen as strategic bet on next-generation CAR-T: analysts

Eli Lilly and Co (NYSE:LLY)’s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building,…

LLY to Buy Oncology Biotech Kelonia Therapeutics for $7 Billion

Eli Lilly is set to acquire Kelonia Therapeutics in a $7B deal, boosting its genetic medicine platform with a novel…

Eli Lilly: Wachstumsstark, strategisch klug und nach Rücksetzer attraktiv!

Die Aktie von Eli Lilly (NYSE: LLY) bleibt aus meiner Sicht ein hochwertiger Wachstumswert mit attraktiven Chance-Risiko-Profil. Mit einem Forward-KGV…

Eli Lilly: We Havent Reached Its Peak Yet (Rating Upgrade)

…

Eli Lilly taps into its GLP-1 windfall, while Honeywell sheds a lower-margin unit

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of…

Eli Lilly: 2 Mrd. USD für die Zukunft der Krebsmedizin!

Eli Lilly (NYSE: LLY) steht kurz vor der Übernahme von Kelonia Therapeutics für mehr als 2 Mrd. USD. Ein bemerkenswerter…

Will Eli Lillys New GLP-1 Pill Get the Stock Get Back to a $1 Trillion Valuation?

Regulators approved the companys GLP-1 weight loss pill, Foundayo, at the beginning of April.…

Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion

Kelonia is developing technology to reprogram patients T-cells inside the body so those cells can attack cancer, called in vivo…

Eli Lilly expands genetic medicine capabilities with Kelonia Therapeutics acquisition

Eli Lilly and Co (NYSE:LLY) has agreed to acquire private clinical-stage biotechnology firm Kelonia Therapeutics in a deal aimed at…

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

A deal could be reached as soon as Monday and could include additional payments tied to Kelonia meeting certain milestones,…

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says

Eli Lilly in advanced talks to acquire Kelonia Therapeutics for over $2 billion, WSJ says…

This Drug Stock Has Crushed the S&P 500 Over the Last Decade

Eli Lilly is leading the GLP-1 charge, but investors have already priced much of the good news into the stock.…

Truist reiterates Eli Lilly stock rating on positive trial data

Truist reiterates Eli Lilly stock rating on positive trial data…

Eli Lillys Oral Drug Clears CV Test, Hims Surges 14%

Eli Lillys oral obesity drug Foundayo passed cardiovascular safety testing while Hims & Hers surged 14% after the FDA scheduled…

Is This $6.3 Billion Deal a Game Changer for Eli Lilly?

Its acquiring an asset with a very promising lead drug candidate.…

Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know

Eli Lilly (LLY) concluded the recent trading session at $905.03, signifying a -1.89% move from its prior days close.…

The $1 Trillion Race: Why Eli Lilly Is Leaving Novo Nordisk in the Dust

And can Novo Nordisk catch up to its rival in the weight loss market?…